Skip to main content
Fig. 5 | Journal of Nanobiotechnology

Fig. 5

From: Synergistic combination of targeted nano-nuclear-reactors and anti-PD-L1 nanobodies evokes persistent T cell immune activation for cancer immunotherapy

Fig. 5

Nanobody binding activity, cellular O2 production, and ICD induction of Fe-PHCN@DOX nano-nuclear-reactors. A The binding activity of PD-L1 antigen with BSA, anti-PD-L1 nanobody (Nab), and anti-PD-L1 antibody (ab) was measured by ELISA. B O2 generation in CT26 cells treated with different groups. The scale bar is 100 μm. The ATP content (C), the HMGB1 level in nuclei (D), and the CRT expression on the surface of CT26 cells (E, F) after different group treatment. G, H Quantification of CD80 and CD86 expression on the surface of DC2.4 cells after different treatment by flow cytometry. I ELISA analysis of the levels of cytokines IL-6 secreted by DC2.4 cells in the medium. The scale bar is 25 μm. The p values were analyzed using the Log-rank (Mantel-Cox) test. Data are presented as the mean ± standard error of the mean. *p < 0.05, **p < 0.01, ***p < 0.001

Back to article page